# Rocket Lab Corp: financial statements, quarterly

RKLB · Nasdaq · CIK 1819994 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rklb.md) · [Financials](/companies/rklb/financials.md) · [Filings](/companies/rklb/filings.md) · [Insiders](/companies/rklb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rklb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [67.7](/filings/0000950170-24-125529.md) | [60.0 d](/filings/0001819994-26-000013.md) | [92.8](/filings/0001628280-25-023857.md) | [106](/filings/0001628280-25-038936.md) | [105](/filings/0001819994-25-000021.md) | [132 d](/filings/0001819994-26-000013.md) | [123](/filings/0001819994-26-000028.md) | [144](/filings/0001819994-26-000062.md) | [155](/filings/0001819994-25-000021.md) | [180 d](/filings/0001819994-26-000013.md) | [200](/filings/0001819994-26-000028.md) | [234](/filings/0001819994-26-000062.md) |
| Cost of revenue | $m | [52.7](/filings/0000950170-24-125529.md) | [44.5 d](/filings/0001819994-26-000013.md) | [68.6](/filings/0001628280-25-023857.md) | [79.1](/filings/0001628280-25-038936.md) | [76.8](/filings/0001819994-25-000021.md) | [95.6 d](/filings/0001819994-26-000013.md) | [87.3](/filings/0001819994-26-000028.md) | [98.1](/filings/0001819994-26-000062.md) | [97.8](/filings/0001819994-25-000021.md) | [111 d](/filings/0001819994-26-000013.md) | [124](/filings/0001819994-26-000028.md) | [149](/filings/0001819994-26-000062.md) |
| Gross profit | $m | [15.0](/filings/0000950170-24-125529.md) | [15.5 d](/filings/0001819994-26-000013.md) | [24.2](/filings/0001628280-25-023857.md) | [27.2](/filings/0001628280-25-038936.md) | [28.0](/filings/0001819994-25-000021.md) | [36.8 d](/filings/0001819994-26-000013.md) | [35.2](/filings/0001819994-26-000028.md) | [46.4](/filings/0001819994-26-000062.md) | [57.3](/filings/0001819994-25-000021.md) | [68.2 d](/filings/0001819994-26-000013.md) | [76.5](/filings/0001819994-26-000028.md) | [84.6](/filings/0001819994-26-000062.md) |
| Research and development | $m | [26.6](/filings/0000950170-24-125529.md) | [37.5 d](/filings/0001819994-26-000013.md) | [38.5](/filings/0001628280-25-023857.md) | [39.9](/filings/0001628280-25-038936.md) | [47.7](/filings/0001819994-25-000021.md) | [48.3 d](/filings/0001819994-26-000013.md) | [55.1](/filings/0001819994-26-000028.md) | [66.1](/filings/0001819994-26-000062.md) | [70.7](/filings/0001819994-25-000021.md) | [78.8 d](/filings/0001819994-26-000013.md) | [80.5](/filings/0001819994-26-000028.md) | [82.4](/filings/0001819994-26-000062.md) |
| Selling, general and administrative | $m | [27.2](/filings/0000950170-24-125529.md) | [25.9 d](/filings/0001819994-26-000013.md) | [28.7](/filings/0001628280-25-023857.md) | [30.5](/filings/0001628280-25-038936.md) | [32.2](/filings/0001819994-25-000021.md) | [40.1 d](/filings/0001819994-26-000013.md) | [39.3](/filings/0001819994-26-000028.md) | [39.9](/filings/0001819994-26-000062.md) | [45.6](/filings/0001819994-25-000021.md) | [40.5 d](/filings/0001819994-26-000013.md) | [51.9](/filings/0001819994-26-000028.md) | [59.7](/filings/0001819994-26-000062.md) |
| Operating income | $m | [(38.9)](/filings/0000950170-24-125529.md) | [(47.9) d](/filings/0001819994-26-000013.md) | [(43.1)](/filings/0001628280-25-023857.md) | [(43.3)](/filings/0001628280-25-038936.md) | [(51.9)](/filings/0001819994-25-000021.md) | [(51.5) d](/filings/0001819994-26-000013.md) | [(59.2)](/filings/0001819994-26-000028.md) | [(59.6)](/filings/0001819994-26-000062.md) | [(59.0)](/filings/0001819994-25-000021.md) | [(51.0) d](/filings/0001819994-26-000013.md) | [(56.0)](/filings/0001819994-26-000028.md) | [(57.5)](/filings/0001819994-26-000062.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [6.8](/filings/0001819994-26-000028.md) | [7.4](/filings/0001819994-26-000062.md) | not reported | not reported | [1.3](/filings/0001819994-26-000028.md) | [0.6](/filings/0001819994-26-000062.md) |
| Income tax | $m | [1.4](/filings/0000950170-24-125529.md) | [1.0 d](/filings/0001819994-26-000013.md) | [0.0](/filings/0001628280-25-023857.md) | [(0.9)](/filings/0001628280-25-038936.md) | [0.9](/filings/0001819994-25-000021.md) | [0.7 d](/filings/0001819994-26-000013.md) | [(0.8)](/filings/0001819994-26-000028.md) | [2.9](/filings/0001819994-26-000062.md) | [(41.1)](/filings/0001819994-25-000021.md) | [11.3 d](/filings/0001819994-26-000013.md) | [(1.8)](/filings/0001819994-26-000028.md) | [5.3](/filings/0001819994-26-000062.md) |
| Net income | $m | [(40.6)](/filings/0000950170-24-125529.md) | [(50.5) d](/filings/0001819994-26-000013.md) | [(44.3)](/filings/0001819994-25-000021.md) | [(41.6)](/filings/0001819994-25-000021.md) | [(51.9)](/filings/0001819994-25-000021.md) | [(52.3) d](/filings/0001819994-26-000013.md) | [(60.6)](/filings/0001819994-26-000062.md) | [(66.4)](/filings/0001819994-26-000062.md) | [(18.3)](/filings/0001819994-25-000021.md) | [(52.9) d](/filings/0001819994-26-000013.md) | [(45.0)](/filings/0001819994-26-000062.md) | [(49.3)](/filings/0001819994-26-000062.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0000950170-24-125529.md) | not reported | [(0.09)](/filings/0001628280-25-023857.md) | [(0.08)](/filings/0001628280-25-038936.md) | [(0.10)](/filings/0001819994-25-000021.md) | not reported | [(0.12)](/filings/0001819994-26-000028.md) | [(0.13)](/filings/0001819994-26-000062.md) | [(0.03)](/filings/0001819994-25-000021.md) | not reported | [(0.07)](/filings/0001819994-26-000028.md) | [(0.08)](/filings/0001819994-26-000062.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0000950170-24-125529.md) | not reported | [(0.09)](/filings/0001628280-25-023857.md) | [(0.08)](/filings/0001628280-25-038936.md) | [(0.10)](/filings/0001819994-25-000021.md) | not reported | [(0.12)](/filings/0001819994-26-000028.md) | [(0.13)](/filings/0001819994-26-000062.md) | [(0.03)](/filings/0001819994-25-000021.md) | not reported | [(0.07)](/filings/0001819994-26-000028.md) | [(0.08)](/filings/0001819994-26-000062.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [141](/filings/0000950170-23-061189.md) | [163](/filings/0001628280-25-008724.md) | [366](/filings/0000950170-24-053646.md) | [341](/filings/0000950170-24-094122.md) | [292](/filings/0000950170-24-125529.md) | [271](/filings/0001819994-26-000013.md) | [303](/filings/0001628280-25-023857.md) | [564](/filings/0001628280-25-038936.md) | [808](/filings/0001819994-25-000021.md) | [829](/filings/0001819994-26-000062.md) | [1,205](/filings/0001819994-26-000028.md) | [2,129](/filings/0001819994-26-000062.md) |
| Current assets | $m | [506](/filings/0000950170-23-061189.md) | [477](/filings/0001628280-25-008724.md) | [726](/filings/0000950170-24-053646.md) | [752](/filings/0000950170-24-094122.md) | [695](/filings/0000950170-24-125529.md) | [693](/filings/0001819994-26-000013.md) | [725](/filings/0001628280-25-023857.md) | [1,006](/filings/0001628280-25-038936.md) | [1,316](/filings/0001819994-25-000021.md) | [1,366](/filings/0001819994-26-000062.md) | [1,800](/filings/0001819994-26-000028.md) | [2,896](/filings/0001819994-26-000062.md) |
| Total assets | $m | [950](/filings/0000950170-23-061189.md) | [941](/filings/0001628280-25-008724.md) | [1,182](/filings/0000950170-24-053646.md) | [1,189](/filings/0000950170-24-094122.md) | [1,153](/filings/0000950170-24-125529.md) | [1,184](/filings/0001819994-26-000013.md) | [1,255](/filings/0001628280-25-023857.md) | [1,553](/filings/0001628280-25-038936.md) | [2,221](/filings/0001819994-25-000021.md) | [2,324](/filings/0001819994-26-000062.md) | [2,820](/filings/0001819994-26-000028.md) | [4,187](/filings/0001819994-26-000062.md) |
| Current liabilities | $m | [304](/filings/0000950170-23-061189.md) | [223](/filings/0001628280-25-008724.md) | [232](/filings/0000950170-24-053646.md) | [266](/filings/0000950170-24-094122.md) | [269](/filings/0000950170-24-125529.md) | [340](/filings/0001819994-26-000013.md) | [348](/filings/0001628280-25-023857.md) | [376](/filings/0001628280-25-038936.md) | [414](/filings/0001819994-25-000021.md) | [334](/filings/0001819994-26-000062.md) | [402](/filings/0001819994-26-000028.md) | [528](/filings/0001819994-26-000062.md) |
| Total liabilities | $m | [365](/filings/0000950170-23-061189.md) | [387](/filings/0001628280-25-008724.md) | [703](/filings/0000950170-24-053646.md) | [733](/filings/0000950170-24-094122.md) | [733](/filings/0000950170-24-125529.md) | [802](/filings/0001819994-26-000013.md) | [824](/filings/0001628280-25-023857.md) | [865](/filings/0001628280-25-038936.md) | [940](/filings/0001819994-25-000021.md) | [603](/filings/0001819994-26-000062.md) | [556](/filings/0001819994-26-000028.md) | [695](/filings/0001819994-26-000062.md) |
| Long-term debt | $m | [0.0](/filings/0000950170-23-061189.md) | [87.6](/filings/0001628280-25-008724.md) | [52.7](/filings/0000950170-24-053646.md) | [50.1](/filings/0000950170-24-094122.md) | [46.9](/filings/0000950170-24-125529.md) | [44.0](/filings/0001819994-26-000013.md) | [57.7](/filings/0001628280-25-023857.md) | [53.7](/filings/0001628280-25-038936.md) | [51.3](/filings/0001819994-25-000021.md) | [1.7](/filings/0001819994-26-000062.md) | [1.7](/filings/0001819994-26-000028.md) | [1.7](/filings/0001819994-26-000062.md) |
| Current portion of debt | $m | [105](/filings/0000950170-23-061189.md) | [17.8](/filings/0001628280-25-008724.md) | [11.0](/filings/0000950170-24-053646.md) | [11.3](/filings/0000950170-24-094122.md) | [11.8](/filings/0000950170-24-125529.md) | [12.0](/filings/0001819994-26-000013.md) | [20.5](/filings/0001628280-25-023857.md) | [16.5](/filings/0001628280-25-038936.md) | [17.1](/filings/0001819994-25-000021.md) | [0.0](/filings/0001819994-26-000013.md) | not reported | not reported |
| Shareholders' equity | $m | [586](/filings/0000950170-24-125529.md) | [555](/filings/0001819994-26-000013.md) | [479](/filings/0001819994-25-000021.md) | [455](/filings/0001819994-25-000021.md) | [420](/filings/0001819994-25-000021.md) | [382](/filings/0001819994-26-000062.md) | [431](/filings/0001819994-26-000062.md) | [688](/filings/0001819994-26-000062.md) | [1,281](/filings/0001819994-25-000021.md) | [1,722](/filings/0001819994-26-000062.md) | [2,264](/filings/0001819994-26-000062.md) | [3,492](/filings/0001819994-26-000062.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(25.2) d](/filings/0000950170-24-125529.md) | [(42.2) d](/filings/0001819994-26-000013.md) | [(2.6)](/filings/0001628280-25-023857.md) | [(13.0) d](/filings/0001628280-25-038936.md) | [(30.9) d](/filings/0001819994-25-000021.md) | [(2.4) d](/filings/0001819994-26-000013.md) | [(54.2)](/filings/0001819994-26-000028.md) | [(23.2) d](/filings/0001819994-26-000062.md) | [(23.5) d](/filings/0001819994-25-000021.md) | [(64.5) d](/filings/0001819994-26-000013.md) | [(50.3)](/filings/0001819994-26-000028.md) | [(84.1) d](/filings/0001819994-26-000062.md) |
| Capital expenditure | $m | [21.0 d](/filings/0000950170-24-125529.md) | [10.4 d](/filings/0001819994-26-000013.md) | [19.2](/filings/0001628280-25-023857.md) | [15.3 d](/filings/0001628280-25-038936.md) | [11.0 d](/filings/0001819994-25-000021.md) | [21.6 d](/filings/0001819994-26-000013.md) | [28.7](/filings/0001819994-26-000028.md) | [32.0 d](/filings/0001819994-26-000062.md) | [45.9 d](/filings/0001819994-25-000021.md) | [49.7 d](/filings/0001819994-26-000013.md) | [27.1](/filings/0001819994-26-000028.md) | [26.0 d](/filings/0001819994-26-000062.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [470](/filings/0000950170-23-061189.md) | [476](/filings/0000950170-24-053646.md) | [480](/filings/0000950170-24-094122.md) | [484](/filings/0000950170-24-125529.md) | [490](/filings/0001628280-25-023857.md) | [494](/filings/0001628280-25-038936.md) | [498](/filings/0001819994-25-000021.md) | [506](/filings/0001819994-26-000028.md) | [515](/filings/0001819994-26-000062.md) | [529](/filings/0001819994-25-000021.md) | [605](/filings/0001819994-26-000028.md) | [630](/filings/0001819994-26-000062.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 598,350,482 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001819994-26-000062.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.